Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ramosetron
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Catholic University of Korea | Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2015
Lead Product(s) : Ramosetron
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Catholic University of Korea | Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramosetron
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2013
Lead Product(s) : Ramosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramosetron
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2012
Lead Product(s) : Ramosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramosetron
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Korean Cancer Study Group | Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2012
Lead Product(s) : Ramosetron
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Korean Cancer Study Group | Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramosetron
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 14, 2011
Lead Product(s) : Ramosetron
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramosetron
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2011
Lead Product(s) : Ramosetron
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramosetron
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2011
Lead Product(s) : Ramosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramosetron
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2010
Lead Product(s) : Ramosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramosetron
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2010
Lead Product(s) : Ramosetron
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable